Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 7
2003 8
2004 11
2005 6
2006 13
2007 5
2008 4
2009 6
2010 11
2011 10
2012 6
2013 7
2014 8
2015 5
2016 10
2017 7
2018 6
2019 7
2020 5
2021 2
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

127 results

Results by year

Filters applied: . Clear all
Page 1
Differential Changes in ACPA Fine Specificity and Gene Expression in a Randomized Trial of Abatacept and Adalimumab in Rheumatoid Arthritis.
Jabado O, Maldonado MA, Schiff M, Weinblatt ME, Fleischmann R, Robinson WH, He A, Patel V, Greenfield A, Saini J, Galbraith D, Connolly SE. Jabado O, et al. Among authors: schiff m. Rheumatol Ther. 2022 Apr;9(2):391-409. doi: 10.1007/s40744-021-00404-x. Epub 2021 Dec 8. Rheumatol Ther. 2022. PMID: 34878629 Free PMC article.
Analysis of patients with rheumatoid arthritis and higher radiographic progression: association of very high radiographic progression but not of intermediately high with worsening of patient-related outcomes.
Thalmann R, von Kempis J, Zgraggen A, Graf N, Schiff M, Sokka T, Dietrich T, Schulze-Koops H, Mueller RB. Thalmann R, et al. Among authors: schiff m. Clin Exp Rheumatol. 2022 Mar;40(3):589-595. doi: 10.55563/clinexprheumatol/jpysud. Epub 2021 May 5. Clin Exp Rheumatol. 2022. PMID: 34001300
Correction to: Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT.
Strand V, Pope J, Tundia N, Friedman A, Camp HS, Pangan A, Ganguli A, Fuldeore M, Goldschmidt D, Schiff M. Strand V, et al. Among authors: schiff m. Arthritis Res Ther. 2020 Jun 9;22(1):137. doi: 10.1186/s13075-020-02238-4. Arthritis Res Ther. 2020. PMID: 32517782 Free PMC article.
Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT.
Strand V, Pope J, Tundia N, Friedman A, Camp HS, Pangan A, Ganguli A, Fuldeore M, Goldschmidt D, Schiff M. Strand V, et al. Among authors: schiff m. Arthritis Res Ther. 2019 Dec 9;21(1):272. doi: 10.1186/s13075-019-2037-1. Arthritis Res Ther. 2019. PMID: 31815649 Free PMC article. Clinical Trial.
Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs.
Strand V, Schiff M, Tundia N, Friedman A, Meerwein S, Pangan A, Ganguli A, Fuldeore M, Song Y, Pope J. Strand V, et al. Among authors: schiff m. Arthritis Res Ther. 2019 Dec 2;21(1):263. doi: 10.1186/s13075-019-2059-8. Arthritis Res Ther. 2019. PMID: 31791386 Free PMC article. Clinical Trial.
Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE).
Fleischmann R, Weinblatt M, Ahmad H, Maldonado MA, Alemao E, Ye J, Schiff M. Fleischmann R, et al. Among authors: schiff m. Rheumatol Ther. 2019 Dec;6(4):559-571. doi: 10.1007/s40744-019-00174-7. Epub 2019 Oct 22. Rheumatol Ther. 2019. PMID: 31642045 Free PMC article.
127 results